Before initiating vorasidenib treatment, assess blood chemistry and liver laboratory tests.
Select patients with grade 2 astrocytoma or oligodendroglioma for treatment with vorasidenib based on the presence of an IDH1 or IDH2 mutation in tumor specimens.